Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 251 CHF 1.46% Market Closed
Market Cap: 201.8B CHF
Have any thoughts about
Roche Holding AG?
Write Note

Net Margin
Roche Holding AG

19.6%
Current
21%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
19.6%
=
Net Income
11.5B
/
Revenue
58.7B

Net Margin Across Competitors

Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.1B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 348B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 150.1B USD
Net Margin
7%
Country IE
Market Cap 147.1B USD
Net Margin
-126%
No Stocks Found

Roche Holding AG
Glance View

Market Cap
200.1B CHF
Industry
Pharmaceuticals

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

ROG Intrinsic Value
432.54 CHF
Undervaluation 42%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
19.6%
=
Net Income
11.5B
/
Revenue
58.7B
What is the Net Margin of Roche Holding AG?

Based on Roche Holding AG's most recent financial statements, the company has Net Margin of 19.6%.